Enlivex Therapeutics Stock Discussion

$Enlivex Therapeutics (ENLV.US)$
Enlivex Receives Regulatory Authorization for the Initiation of a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis
Wednesday, 11th December at 8:30 am
Ness-Ziona, Israel, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (NASDAQ: ENLV, the "Company")), a clinical-stage macrophage reprogramming immunotherapy company, today announced that the Israeli Ministry of Health authorized the initiation of an investigator-initiated Phase ...

$Enlivex Therapeutics (ENLV.US)$ Benzinga· just
Enlivex Therapeutics Receives Regulatory Authorization From Israeli Ministry Of Health For Initiation Of Phase I Trial Evaluating Allocetra In Patients With TMJ Osteoarthritis

$Enlivex Therapeutics (ENLV.US)$
Enlivex Announces Positive Interim Efficacy Data from Allocetra Trial in Patients with Moderate to Severe Knee Osteoarthritis
Tuesday, 3rd December at 8:30 am
Nes-Ziona, Israel, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (NASDAQ: ENLV, the "Company")), a clinical-stage macrophage reprogramming immunotherapy company, today announced positive interim efficacy data from the Phase I stage of its randomized, multi-country Phase I/II Allocetra™ tri...

$Enlivex Therapeutics (ENLV.US)$
Enlivex Adopts Bitcoin Treasury Reserve Strategy

$Enlivex Therapeutics (ENLV.US)$ Benzinga· 1 min ago
Enlivex Board Approves Purchase Of Up To $1M Of Bitcoin

$Enlivex Therapeutics (ENLV.US)$
Enlivex Announces the Dosing of the First Patient in a Phase I Clinical Trial Evaluating Allocetra in Patients with Psoriatic Arthritis
Enlivex Therapeutics has initiated a Phase I clinical trial evaluating Allocetra™ in patients with psoriatic arthritis. The first patient has completed dosing and initial follow-up with no safety concerns reported. The trial aims to recruit six patients who haven't responded adequately to conventional therapies. The study wi...

$Enlivex Therapeutics (ENLV.US)$
Enlivex Announces the Enrollment and Dosing of the First 10 Patient in the Randomized Phase II Stage of its Allocetra Trial in Patients with Moderate to Severe Knee Osteoarthritis

$Enlivex Therapeutics (ENLV.US)$
Enlivex Receives Authorization from the Danish Medicines Agency to Initiate the Phase II Stage of its Phase I/II Trial of Allocetra in Patients with Moderate to Severe Knee Osteoarthritis

$Enlivex Therapeutics (ENLV.US)$
Enlivex Announces Positive DSMB Recommendation to Initiate the Phase II Stage of its Phase I/II Trial of Allocetra in Patients with Moderate to Severe Knee Osteoarthritis
Nes-Ziona, Israel, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (NASDAQ:ENLV, the "Company"))), a clinical-stage macrophage reprogramming immunotherapy company, today announced that the independent Data and Safety Monitoring Board (DSMB) has completed an interim data review at...